Spero Therapeutics Inc (SPRO)
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for multidrug-resistant bacterial infections and certain rare diseases in the United States. Its pipeline includes tebipenem HBr, an oral carbapenem antibiotic in Phase 3 development for complicated urinary tract infections, including pyelonephritis in adults, and SPR720, a candidate being developed for first-line treatment of nontuberculous mycobacterial pulmonary disease. The company also has collaboration and license arrangements with Meiji Seika Pharma Co., Ltd. for tebipenem HBr, Everest Medicines for SPR206 in Greater China, South Korea, and Southeast Asia, and Vertex Pharmaceuticals Incorporated covering patents related to SPR720 and SPR719. Spero Therapeutics was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SPRO
|
$1.91
|
35.3% Upside
|
Undervalued
|
$4
|
183.7% Upside
|
Bargain
|
Great
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
5.3x
|
1.5x
|
1.3x
|
83.378 M
|
27.697 M
|
2.9%
|
80.1%
|
0.2
|
—
|
47.5%
|
